• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.

作者信息

Bacha Fida

机构信息

Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.

出版信息

Lancet Child Adolesc Health. 2019 Sep;3(9):595-597. doi: 10.1016/S2352-4642(19)30236-6. Epub 2019 Jul 22.

DOI:10.1016/S2352-4642(19)30236-6
PMID:31345736
Abstract
摘要

相似文献

1
FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.美国食品药品监督管理局批准胰高血糖素样肽-1受体激动剂（利拉鲁肽）用于儿童。
Lancet Child Adolesc Health. 2019 Sep;3(9):595-597. doi: 10.1016/S2352-4642(19)30236-6. Epub 2019 Jul 22.
2
Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.社论：某些胰高血糖素样肽-1受体激动剂（GLP-1 RA）能否降低2型糖尿病的大血管并发症——关于利拉鲁肽在糖尿病中的疗效和作用：心血管结局结果评估（LEADER）试验的评论
Curr Vasc Pharmacol. 2016;14(5):469-473. doi: 10.2174/1570161114666160909161537.
3
Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.医疗保险人群中2型糖尿病患者对胰高血糖素样肽-1受体激动剂（GLP-1RA）治疗的依从性
Adv Ther. 2017 Mar;34(3):658-673. doi: 10.1007/s12325-016-0470-y. Epub 2017 Jan 11.
4
Liraglutide.利拉鲁肽。
Nat Rev Drug Discov. 2010 Apr;9(4):267-8. doi: 10.1038/nrd3148.
5
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.用注射药物满足2型糖尿病治疗中未满足的需求：胰高血糖素样肽-1受体激动剂
J Fam Pract. 2017 Oct;66(10 Suppl):S12-S16.
6
Liraglutide for Type 2 diabetes and obesity: a 2015 update.利拉鲁肽用于2型糖尿病和肥胖症：2015年更新
Expert Rev Cardiovasc Ther. 2015;13(7):753-67. doi: 10.1586/14779072.2015.1054810.
7
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.使用基础胰岛素和胰高血糖素样肽-1受体激动剂联合治疗2型糖尿病，以满足未被满足的治疗需求
J Fam Pract. 2017 Oct;66(10 Suppl):S17-S28.
8
[Effects of GLP-1 receptor agonists on carbohydrate metabolism control].胰高血糖素样肽-1受体激动剂对碳水化合物代谢控制的影响
Med Clin (Barc). 2014;143 Suppl 2:18-22. doi: 10.1016/S0025-7753(14)70104-6.
9
Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.使用胰高血糖素样肽-1受体激动剂治疗的青年型5型成年发病糖尿病：一例报告。
Medicine (Baltimore). 2020 Aug 28;99(35):e21939. doi: 10.1097/MD.0000000000021939.
10
Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.2 型糖尿病的固定剂量复方治疗：关于胰岛素和胰高血糖素样肽-1 受体激动剂联合治疗，您应该了解的十大要点。
Postgrad Med. 2018 May;130(4):375-380. doi: 10.1080/00325481.2018.1450058. Epub 2018 Mar 20.

引用本文的文献

1
Predictors of BMI reduction with phentermine/topiramate in adolescents with obesity.肥胖青少年使用苯丁胺/托吡酯降低体重指数的预测因素
Int J Obes (Lond). 2025 Jun 15. doi: 10.1038/s41366-025-01821-6.
2
Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.SGLT2抑制剂在儿科患者和年轻成人中的疗效与安全性：一项随机对照试验的系统评价和荟萃分析
Pediatr Diabetes. 2024 Oct 22;2024:6295345. doi: 10.1155/2024/6295345. eCollection 2024.
3
Insights into therapeutic approaches for the treatment of neurodegenerative diseases targeting metabolic syndrome.
针对代谢综合征治疗神经退行性疾病的治疗方法见解。
Mol Biol Rep. 2025 Feb 21;52(1):260. doi: 10.1007/s11033-025-10346-0.
4
Parent and Guardian Opinions on Obesity Medications Use in Adolescents with Obesity and Related Comorbidities.家长和监护人对肥胖青少年及其相关合并症使用肥胖症药物的看法。
Child Obes. 2025 Jun;21(4):365-371. doi: 10.1089/chi.2024.0351. Epub 2024 Dec 18.
5
Association of Patient and Geographic Variables in Pediatric Patients With Prediabetes Becoming Lost to Follow-up.糖尿病前期儿科患者失访与患者及地理变量的关联
J Endocr Soc. 2024 Sep 6;8(10):bvae157. doi: 10.1210/jendso/bvae157. eCollection 2024 Aug 27.
6
Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective.胰高血糖素样肽-1受体激动剂在1型糖尿病管理中的应用：儿科视角
Horm Res Paediatr. 2025;98(4):405-424. doi: 10.1159/000541228. Epub 2024 Sep 2.
7
Exenatide for obesity in children and adolescents: Systematic review and meta-analysis.艾塞那肽用于儿童和青少年肥胖症：系统评价与荟萃分析。
Front Pharmacol. 2024 Apr 3;15:1290184. doi: 10.3389/fphar.2024.1290184. eCollection 2024.
8
Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).胰高血糖素样肽-1受体激动剂——治疗儿童代谢功能障碍相关脂肪性肝病（MASLD）的一种潜在新药。
Children (Basel). 2024 Feb 23;11(3):275. doi: 10.3390/children11030275.
9
Prediabetes in children and adolescents: An updated review.儿童和青少年的糖尿病前期：最新综述。
World J Clin Pediatr. 2023 Dec 9;12(5):263-272. doi: 10.5409/wjcp.v12.i5.263.
10
Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov.胰高血糖素样肽-1在儿童肥胖症中的应用；Clinicaltrials.gov的最新综述
J Multidiscip Healthc. 2023 Jul 31;16:2179-2187. doi: 10.2147/JMDH.S419245. eCollection 2023.